Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients

Radiotherapy and Oncology

Volumn 90, Issue 1, 2009, Pages 116-121

  Magné, Nicolas ^a,b   Castadot, Pierre ^a   Chargari, Cyrus ^b   Di Leo, Angelo ^a,c   Philippson, Catherine ^a   Van Houtte, Paul ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HOSPITAL OF PRATO   (Italy)

Author keywords

Breast cancer; Cardiac toxicity; Docetaxel; Doxorubicin; Radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CARDIOVASCULAR RISK; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 58149235023     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.003     Document Type: Article

References (32)

1. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
2. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
3. Vinh-Hung V., and Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 96 (2004) 115-121
4. Adams M.J., Hardenbergh P.H., Constine L.S., and Lipshultz S.E. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45 (2003) 55-75
5. Cuzick J., Stewart H., Rutqvist L., Houghton J., Edwards R., Redmond C., et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12 (1994) 447-453
6. Harris E.E.R., Correa C., Hwang W.T., Liao J., Litt H.I., Ferrari V.A., et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24 (2006) 4100-4166
7. Hojris I., Overgaard M., Christensen J.J., and Overgaard J. Morbidity and mortality of ischaemiac heart disease 3083 high-risk breast cancer patients given adjuvant systemic therapy treatment with or without postmastectomy irradiation: analysis of DBCG 82b and 82c randomised trials. Lancet 354 (1999) 1425-1430
8. Jagsi R., Griffith K.A., Koelling T., Roberts R., and Pierce L.J. Rates of myocardial infraction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer 109 (2007) 650-657
9. Paszat L., Mackillop W.J., Groome P.A., Boyd C., Schulze K., and Holowaty E. Mortality from myocardial infraction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology and end-results cancer registries. J Clin Oncol 16 (1998) 2625-2631
10. Patt D.A., Goodwin J.S., Kuo Y.F., Freeman J.L., Zhang D.D., Buchholz T.A., et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 23 (2005) 7125-7134
11. Rutqvist L.E., Rose C., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol 42 (2003) 532-545
12. Darby S., McGale P., Peto R., Granath F., Hall P., and Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90,000 Swedish women. BMJ 326 (2003) 256-257
13. Hurkmans C.W., Cho B.C.J., Damen E., Zijp L., and Mijnheer B.J. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol 62 (2002) 163-171
14. Korreman S.S., Pedersen A.N., Josipovic M., Aarup L.R., Juhler-Nottrup T., Specht L., et al. Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy. Radiother Oncol 80 (2006) 257-262
15. Pierce L.J., Butler J.B., Martel M.K., Normolle D.P., Koelling T., Marsh R.B., et al. Postmastectomy radiotherapy of the chest wall: dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys 52 (2002) 1220-1230
16. Pierce L.J., Lichter A.S., and Archer P. Indications, integration, and technical aspects of local-regional irradiation in the management of advanced breast cancer. Semin Radiat Oncol 4 (1994) 242-253
17. Pierce L.J. Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer. J Natl Cancer Inst Monogr 30 (2001) 117-124
18. Strom E.A. Breast IMRT: new tools leading to new vision. Int J Radiat Oncol Biol Phys 54 (2002) 1297-1298
19. Biganzoli L., Cufer T., Bruning P., Coleman R., Duchateau L., Calvert A.H., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-lie chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20 (2002) 3114-3121
20. Mamounas E.P., and Sledge Jr. G.W. Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol 28 (2001) 24-31
21. Francis P., Crown J., Di Leo A., Buyse M., Balil A., Andersson M., et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100 (2008) 121-133
22. Cardoso F., Ferreira Filho A.F., Crown J., Dolci S., Paesmans M., Riva A., et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 21 (2001) 789-795
23. Ferreira Filho A.F., Crown J., Cardoso F., Nogaret J.M., Duffy K., Dolci S., et al. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. Anticancer Res 22 (2002) 2471-2476
24. Martin M., Lluch A., Ojeda B., Barnabas A., Colomer R., Massuti B., et al. Paclitaxel plus doxorubicin in metastatic breast cancer preliminary analysis cardiotoxicity. Semin Oncol 24 (1997) 17-26
25. Ferrero J.M., Magné N., Foa C., Largillier R., and Namer M. Cardiac tolerability of paclitaxel-anthracycline associations in breast cancer management. Bull Cancer 90 (2003) 219-226
26. Gennari A., Salvadori B., Donati S., Bengala C., Orlandini C., Danesi R., et al. Cardiotoxicty of epirubicin.paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 17 (1999) 3596-3602
27. Giordano S.H., Booser D.J., Murray J.L., Ibrahim N.K., Rahman Z.U., Valero V., et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8 (2002) 3360-3368
28. Magné N., Largillier R., Marcy P.Y., Magné J., and Namer M. Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Support Care Cancer 13 (2005) 819-825
29. Callahan R.J., Froelich J.W., McKusick K.A., Leppo J., and Strauss H.W. A modified method for the in vivo labeling of red blood cells with Tc-99m: concise communication. J Nucl Med 23 (1982) 315-318
30. Massardo T., Gal R.A., Grenier R.P., Schmidt D.H., and Port S.C. Left ventricular volume calculation using a count-based ratio-method applied to multigated radionuclide angiography. J Nucl Med 31 (1990) 450-456
31. Hardenbergh P.H., Recht A., Gollamudi S., Come S.E., Hayes D.F., Shulman L.N., et al. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys 45 (1999) 69-72
32. Hooning M.J., Aleman B.M.P., van Rosmalen A.J.M., Kuenen M.A., Klijn J.G.M., and van Leeuwen F.E. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 64 (2006) 1081-1091